In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...

In July, Teva announced positive...

08/08/2024

Neurology

News

High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke

08/08/2024

Jolynn Tumolo ;

Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.

Compared with moderate-dose...

08/08/2024

Neurology

An illustration of a healthcare provider conducting a telehealth appointment

News

Teleneurology Visits Acceptable to Patients Across Neurologic Conditions

08/05/2024

Jolynn Tumolo ;

Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.

Regardless of their neurologic...

08/05/2024

Neurology

The US Food and Drug Administration headquarters sign.

News

DMD Gene Therapy Indication Expanded to Include Boys 4 and Older

08/01/2024

Jolynn Tumolo ;

The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...

The US FDA approved an...

08/01/2024

Neurology

A person walks down a boarded path with sunlight and trees in the background

News

Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS

07/30/2024

Jolynn Tumolo ;

Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).

Backward walking speed reserve,...

07/30/2024

Neurology

News

FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment

07/29/2024

Evi Arthur ;

VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

VYVGART Hytrulo (efgartigimod...

07/29/2024

Neurology

News

Moderate Physical Activity May Mitigate ALS Risk for Male Patients

07/25/2024

Brionna Mendoza ;

Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.

Male individuals who engage in...

07/25/2024

Neurology

News

Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy

07/23/2024

Jolynn Tumolo ;

The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.

The US Food and Drug...

07/23/2024

Neurology

News

Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults

07/22/2024

Evi Arthur ;

Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.

Chronic loneliness was...

07/22/2024

Neurology

a hand breaks a wooden human figurine in half

News

Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse

07/18/2024

Jolynn Tumolo ;

The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.

The calcitonin gene-related...

07/18/2024

Neurology

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources

11/19/2020

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...

Early Alzheimer’s Disease:...

11/19/2020

Neurology

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data

11/17/2020

Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...

Emerging Treatments for Early...

11/17/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 

Emerging Treatments for Early...

11/12/2020

Neurology

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology

11/12/2020

Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series

Early Alzheimer’s Disease...

11/12/2020

Neurology

Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

11/12/2020

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...

Emerging Treatments for Early...

11/12/2020

Neurology

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease

11/10/2020

Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 

Current Treatment Limitations...

11/10/2020

Neurology

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

Migraine CME Series

News

Alzheimer's Disease CME Series

Specialties

Events

Year Round Education

HMP Global Products